Galapagos offloads its CAR-T programs after a year of strategic retreat
Lakefront Biotherapeutics, the new name for Galapagos Therapeutics, has finally found a buyer for the cell therapy assets it spent months trying to move on. The programs have gone to fellow Belgian biotech Armed Cell Therapeutics in a deal worth €8 million upfront and as much as €230 million in milestones.
For Galapagos, the transaction closes a difficult chapter. The company had already stepped away from CAR-T development after deciding to exit the space and refocus on a T-cell engager from Ouro Medicines, a program it received through Gilead Sciences. This sale gives the abandoned pipeline a new home and a better chance of advancing beyond the preclinical stage, although the development burden now shifts entirely to ACT.
The assets themselves are not clinical-stage programs. They are a preclinical portfolio built around “multi-targeting and armed CAR-T constructs” intended to improve potency and persistence while limiting treatment resistance in hematological cancers and solid tumors with high unmet need. In practical terms, the scientific bet is clear: standard CAR-T approaches can lose steam when tumor cells escape recognition or when engineered T cells fail to remain active long enough in the body. Multi-targeting designs and armed constructs are meant to address both failures at once.
A preclinical portfolio built to outlast resistance
The commercial logic of the deal mirrors the biological one. CAR-T therapies have transformed parts of hematologic oncology, but durability remains a major challenge, and the problem becomes harder in solid tumors, where the tumor microenvironment suppresses immune activity and antigen loss can blunt response. A design that tries to strengthen persistence and widen target coverage is aiming squarely at those weak points.
ACT will independently advance the portfolio, and the company was created by Galapagos’ former chief executive Paul Stoffels. The move keeps the assets in Belgian hands and gives ACT a built-in scientific rationale for its launch. Rather than building from scratch, the new company enters the field with a defined preclinical package and a stated focus on cancer types that still leave clinicians with limited options.
Lakefront’s chief business officer, Sooin Kwon, framed the divestiture as a way to keep the early-stage work alive on behalf of patients. The message also reflects the company’s newer identity. Lakefront now says it has a newly established pipeline of T-cell engagers and a strong cash balance, which suggests the company has no intention of returning to the cell therapy strategy it abandoned.
The old CAR-T ambitions trace back to AboundBio, which Galapagos bought for $14 million in 2022 for its fully human antibody-based library and drug discovery capabilities. At the time, the plan was to move three next-generation CAR-T candidates from that library into the clinic over three years. Those ambitions never matured into a sustained development engine.
What Galapagos tried to build, and why it unraveled
The collapse of the cell therapy strategy unfolded quickly. By October 2025, Galapagos had backed away from the modality only 10 months after signaling it would focus on it while spinning off another company to build an innovative medicines pipeline. Henry Gosebruch, who succeeded Stoffels as chief executive, later said the company had tried to place the cell therapy portfolio with multiple strategic players, but none showed serious interest in the business.
Faced with that limited market, Galapagos opted to wind down the cell therapy unit. The closure was expected to affect about 365 employees across Europe, the U.S. and China, with two U.S. facilities and one site each in the Netherlands, Switzerland and China scheduled for closure. The financial impact was steep: Galapagos took a €228 million hit from the shutdown.
That sequence matters because it shows how quickly a biopharma thesis can collapse when a platform fails to attract external conviction. Cell therapy remains scientifically compelling, but the bar for capital deployment is high, especially when programs are still preclinical and require substantial follow-on investment before any human data can support valuation.
Gilead’s influence still shapes Lakefront’s direction
Gilead’s role remains central in the background. The company owns 25% of Galapagos and pushed the biopharma toward clinical-stage assets in immunology or oncology after the cell therapy retreat. In March, Gilead delivered Ouro’s BCMAxCD3 T-cell engager to the reorganized company after buying Ouro for $1.67 billion and expecting Galapagos to cover half of the upfront cost.
That shift tells an important story about portfolio discipline. T-cell engagers and CAR-T therapies both aim to redirect immune activity toward malignant cells, but they differ in logistics, manufacturing demands and the ease with which they can be scaled. An injectable T-cell engager can often be developed and deployed with far less operational complexity than an autologous cell therapy program that depends on individualized cell collection, engineering and reinfusion. For a company under pressure to rebuild, that difference is not merely structural; it changes how quickly a pipeline can reach proof of concept.
ACT now inherits the harder, longer road. Preclinical assets can be intriguing, but they do not yet answer the questions that ultimately determine value in oncology: whether the engineered cells can expand, persist, traffic to tumors and avoid exhaustion without creating unacceptable toxicity. Until those questions are answered in humans, the promise stays in the laboratory.
The new owner does at least begin with a coherent scientific premise. If armed and multi-targeting CAR-T designs can do what traditional constructs have struggled to do — maintain activity, resist escape and extend benefit into solid tumors — the portfolio could still become meaningful. For now, though, the transaction is best understood as a transfer of risk from a company that no longer wants it to one that is willing to bet that the next iteration of CAR-T can overcome the field’s most stubborn limitations.